Amendment: SEC Form SC 13G/A filed by Regulus Therapeutics Inc.

11/14/24 2:35:48 PM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $RGLS alert in real time by email

SC 13G/A 1 dafna13grgls3Q2024.txt UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No.1)* REGULUS THERAPEUTICS INC. (Name of Issuer) Common Stock, No Par Value (Title of Class Securities) 75915K309 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed:** [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosure provided in a prior cover page. ** Nathan Fischel, Fariba Ghodsian and DAFNA Capital Management, LLC are filing this Schedule 13G pursuant to Rule 13d-1(b). The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. CUSIP No. 75915K309 1.NAME OF REPORTING PERSONS. I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY). DAFNA Capital Management, LLC 36-4334068 2.CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS) (A) [ ] (B) [ ] 3.SEC USE ONLY 4.CITIZENSHIP OR PLACE OF ORGANIZATION Delaware NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 5.SOLE VOTING POWER 895,200 6.SHARED VOTING POWER 0 7.SOLE DISPOSITIVE POWER 895,200 8.SHARED DISPOSITIVE POWER 0 9.AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 895,200 10.CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) 11.PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 1.37% 12.TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) IA CUSIP No. 75915K309 1.NAME OF REPORTING PERSONS. I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY). Nathan Fischel 2.CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS) (A) [ ] (B) [ ] 3.SEC USE ONLY 4.CITIZENSHIP OR PLACE OF ORGANIZATION Austria citizen (U.S. permanent resident) NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 5.SOLE VOTING POWER 895,200 6.SHARED VOTING POWER 0 7.SOLE DISPOSITIVE POWER 895,200 8.SHARED DISPOSITIVE POWER 0 9.AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 895,200 10.CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) 11.PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 1.37% 12.TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) IN, HC CUSIP No. 75915K309 1.NAME OF REPORTING PERSONS. I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY). Fariba Ghodsian 2.CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS) (A) [ ] (B) [ ] 3.SEC USE ONLY 4.CITIZENSHIP OR PLACE OF ORGANIZATION United States of America NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 5.SOLE VOTING POWER 895,200 6.SHARED VOTING POWER 0 7.SOLE DISPOSITIVE POWER 895,200 8.SHARED DISPOSITIVE POWER 0 9.AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 895,200 10.CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) 11.PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 1.37% 12.TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) IN, HC Item 1. (a) Name of Issuer Regulus Therapeutics Inc. (b) Address of Issuer's Principal Executive Offices 4224 Campus Point Court, Suite 210, San Diego, California 92121 Item 2. (a) Name of Person Filing This Schedule 13G is being filed on behalf of DAFNA Capital Management, LLC, Nathan Fischel and Fariba Ghodsian (each, a "Reporting Person"). (b) Address of Principal Business office or, if None, Residence For each Reporting Person, 10990 Wilshire Boulevard, Suite 1400 Los Angeles, CA 90024 (c) Citizenship DAFNA Capital Management, LLC is a Delaware limited liability company. Dr. Fischel is a citizen of Austria and a U.S. permanent resident. Dr. Ghodsian is a citizen of the United States. (d) Title of Class of Securities Common Stock (e) CUSIP Number 75915K309 Item 3. If this statement is filed pursuant to ss. 240.13d-1(b), or 240.13d-2(b) or (c), check whether the person filing is a: (a) [ ] Broker or dealer registered under section 15 of the Act (15 U.S.C. 78c). (b) [ ] Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c). (c) [ ] Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c). (d) [ ] Investment company registered under section 8 of the Investment Company Act (15 U.S.C. 80a-8). (e) [x] An investment adviser in accordance with ss. 240.13d-1(b)(1)(ii)(E).* (f) [ ] An employee benefit plan or endowment fund in accordance with ss. 240.13d-1(b)(ii)(F). (g) [x] A parent holding company or control person in accordance with ss. 240.13d-1(b)(1)(ii)(G).** (h) [ ] A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813). (i) [ ] A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a 3). (j) [ ] Group in accordance with ss. 240.13d-1(b)(ii)(J). * DAFNA Capital Management, LLC is an investment adviser in accordance with ss. 240.13d-1(b)(1)(ii)(E). ** Drs. Fischel and Ghodsian are control persons of DAFNA Capital Management, LLC in accordance with ss. 240.13d-1(b)(1)(ii)(G). Item 4. Ownership For each Reporting Person: (a) Amount beneficially owned: 895,200 (the "Shares") (b) Percent of class: 1.37%* (c) Number of shares to which the Reporting Person has: (i) Sole power to vote or to direct the vote: 895,200 (ii) Shared power to direct the vote: 0 (iii) Sole power to dispose or to direct the disposition of: 895,200 (iv) Shared power to dispose or to direct the disposition of: 0 *The ownership percentage is calculated based on 65,500,134 shares of Common Stock outstanding as of November 1, 2024, as reported in the issuer's most recent Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2024, as filed with the Securities and Exchange Commission on November 7, 2024. Item 5. Ownership of Five Percent or Less of a Class. If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class securities, check the following [x] Item 6. Ownership of More than Five Percent on Behalf of Another Person. DAFNA Capital Management, LLC, in its capacity as investment adviser to DAFNA LifeScience, L.P. and DAFNA LifeScience Select, L.P. (collectively, the "Funds"), may be deemed to be the beneficial owner of the Shares owned by the Funds, as in its capacity as investment adviser it has the power to dispose, direct the disposition of, and vote the shares of the issuer owned by the Funds. Nathan Fischel is a part-owner of DAFNA Capital Management, LLC and CEO. As a controlling person of DAFNA Capital Management, LLC, he may be deemed to beneficially own the Shares of the issuer owned by the Funds. Fariba Ghodsian is a part-owner of DAFNA Capital Management, LLC and Chief Investment Officer. As a controlling person of DAFNA Capital Management, LLC, she may be deemed to beneficially own the Shares of the issuer owned by the Funds. Pursuant to Rule 13d-4, Drs. Fischel and Ghodsian disclaim beneficial ownership of the securities owned by the Funds. Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company. N/A Item 8. Identification and Classification of Members of the Group. N/A Item 9. Notice of Dissolution of Group. N/A Item 10.Certification: By signing below, I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose or with the effect of changing or influencing the control of the issuer and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. SIGNATURE After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Date: November 14,2024 DAFNA Capital Management, LLC By: /s/ Nathan Fischel Nathan Fischel,MD, CFA, CEO /s/ Nathan Fischel Nathan Fischel, MD, CFA /s/ Fariba Ghodsian Fariba Ghodsian, D.Phil., MBA Exhibit A Joint Filing Agreement Pursuant to Rule 13d-1 This agreement is made pursuant to Rule 13d-l(k)(1) under the Securities and Exchange Act of 1934, as amended (the "Act") by and among the parties listed below, each referenced to herein as a "Joint Filer". The Joint Filers agree that a statement of beneficial ownership as required by Sections 13(g) or 13(d) of the Act and the Rules thereunder may be filed on each of their behalf on Schedule 13G or Schedule 13D, as appropriate, and that said joint filing may thereafter be amended by further joint filings. The Joint Filers state that they each satisfy the requirements for making a joint filing under Rule 13d-1. Date: November 14, 2024 DAFNA Capital Management, LLC By: /s/ Nathan Fischel Nathan Fischel, MD, CFA, CEO /s/ Nathan Fischel Nathan Fischel, MD, CFA /s/ Fariba Ghodsian Fariba Ghodsian, D.Phil., MBA

Get the next $RGLS alert in real time by email

Date

Price Target

Rating

Analyst

3/27/2025

$3.00 → $6.00

Equal Weight → Overweight

Wells Fargo

8/2/2024

$7.00

Outperform

Oppenheimer

3/18/2024

$6.00

Outperform

Leerink Partners

9/2/2021

$2.00

Overweight

Cantor Fitzgerald

Amendment: SEC Form SC 13G/A filed by Regulus Therapeutics Inc.

11/14/24 2:35:48 PM ET

$RGLS

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $RGLS alert in real time by email

Date

Price Target

Rating

Analyst

3/27/2025

$3.00 → $6.00

Equal Weight → Overweight

Wells Fargo

8/2/2024

$7.00

Outperform

Oppenheimer

3/18/2024

$6.00

Outperform

Leerink Partners

9/2/2021

$2.00

Overweight

Cantor Fitzgerald

Amendment: SEC Form SC 13G/A filed by Regulus Therapeutics Inc.

Crush Q3 2025 with the Best AI Superconnector

Recent Analyst Ratings for
$RGLS

Amendment: SEC Form SC 13G/A filed by Regulus Therapeutics Inc.

Crush Q3 2025 with the Best AI Superconnector

Recent Analyst Ratings for
$RGLS

$RGLS
Insider Trading

Director Rastetter William H returned 57,292 shares to the company (SEC Form 4)

Director Witz Pascale returned 67,233 shares to the company, closing all direct ownership in the company (SEC Form 4)

Director Papadopoulos Stelios returned 64,635 shares to the company, closing all direct ownership in the company (SEC Form 4)

$RGLS
SEC Filings

SEC Form 15-12G filed by Regulus Therapeutics Inc.

SEC Form EFFECT filed by Regulus Therapeutics Inc.

SEC Form EFFECT filed by Regulus Therapeutics Inc.

$RGLS
Analyst Ratings

Regulus Therapeutics upgraded by Wells Fargo with a new price target

Oppenheimer initiated coverage on Regulus Therapeutics with a new price target

Leerink Partners initiated coverage on Regulus Therapeutics with a new price target

$RGLS
Insider Purchases

President & Head of R & D Klassen Preston bought $95,852 worth of shares (12,000 units at $7.99), increasing direct ownership by 33% to 48,055 units (SEC Form 4)

Chief Executive Officer Hagan Joseph P bought $54,260 worth of shares (50,000 units at $1.09), increasing direct ownership by 24% to 260,808 units (SEC Form 4)

Director Baltimore David bought $20,787 worth of shares (19,610 units at $1.06), increasing direct ownership by 766% to 22,169 units (SEC Form 4)

$RGLS
Press Releases

Regulus Therapeutics Reports First Quarter 2025 Financial Results and Recent Updates

Regulus Therapeutics Enters into Agreement to be Acquired by Novartis AG

Regulus Therapeutics to Present at the 2025 Oppenheimer Innovation on the Island Biotech Summit

$RGLS
Large Ownership Changes